These Analysts Boost Their Forecasts On Sage Therapeutics Following Q4 Results
Portfolio Pulse from Avi Kapoor
Sage Therapeutics, Inc. (NASDAQ:SAGE) reported Q4 revenue surpassing expectations at $77.97 million against estimates of $60.98 million. The company highlighted the successful launch of ZURZUVAE for postpartum depression. Following the results, RBC Capital and HC Wainwright & Co. raised their price targets for SAGE, despite a slight 0.2% drop in its shares to $25.71.
February 15, 2024 | 5:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sage Therapeutics reported higher-than-expected Q4 revenue and received price target upgrades from RBC Capital and HC Wainwright & Co. following the successful launch of ZURZUVAE.
The positive earnings report and subsequent analyst upgrades typically signal investor confidence and can lead to short-term stock price appreciation. The successful launch of ZURZUVAE further strengthens the company's market position, potentially increasing its stock value.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100